title: G protein-coupled receptors as therapeutic targets for obesity and type 2 diabetes.
abstract: The prevalence of obesity and type 2 diabetes, two strongly correlated disorders, is increasing worldwide. Weight loss can reduce the risk of developing type 2 diabetes and the pharmacological treatments normally required to manage this disorder. Even though dietary and lifestyle changes may eventually reduce obesity for some individuals, new safe and more efficacious drugs are required for successful weight reduction and treatment of type 2 diabetes in a large proportion of obese individuals. In addition to targeting known G protein-coupled receptors (GPCRs), several orphan GPCRs expressed in central nervous system areas known to regulate feeding may provide new targets for the treatment of obesity. Similarly, the pancreas contains numerous islet GPCRs as well as an abundance of orphan GPCRs that potentially could emerge as targets for future antidiabetic compounds. One of the major challenges facing the pharmaceutical industry is how to rapidly establish the function and therapeutic relevance of orphan GPCRs, some of which may represent novel targets for the discovery of the next generation of drugs to effectively treat obesity and type 2 diabetes. This review will focus on the significant potential of known and orphan GPCRs as targets for the discovery of new drugs to successfully treat these serious disorders.
authors.affiliation: Division of Metabolic Research, Arena Pharmaceuticals, 6166 Nancy Ridge Drive, San Diego, CA 92121, USA. CBjenning@arenapharm.com
authors.forename: Christina
authors.initials: C
authors.lastname: Bjenning
authors.forename: Hussien
authors.initials: H
authors.lastname: Al-Shamma
authors.forename: William
authors.initials: W
authors.lastname: Thomsen
authors.forename: Jim
authors.initials: J
authors.lastname: Leonard
authors.forename: Dominic
authors.initials: D
authors.lastname: Behan
mesh_terms: D000818:Animals; D001069:Appetite Regulation / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D004734:Energy Metabolism / Q000187:drug effects; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D008024:Ligands; D009765:Obesity / Q000188:drug therapy* / Q000378:metabolism; D043562:Receptors, G-Protein-Coupled / Q000378:metabolism*
chemical_list: D007004:Hypoglycemic Agents; D008024:Ligands; D043562:Receptors, G-Protein-Coupled